BIRC5 and neuroblastoma: Notably, the New Drug Development Strategy (NDDS, a project of Innovative Therapies for Children with Cancer, the European Network for Cancer Research in Children and Adolescents, and the International Society of Paediatric Oncology Europe Neuroblastoma) has categorized survivin as a high priority drug target in neuroblastoma and YM155 as a high priority drug [22].